Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177 Lu] Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) - Ahmadzadehfar, H; Rahbar, K; Baum, RP (European Journal of Nuclear Medicine and Molecular Imaging, 2021)